Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2019-01-09 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
联合信用评级有限公司关于公司收到中国证监会山东监管局警示函的关注公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding a warning letter received by the company from the China Securities Regulatory Commission Shandong Bureau. It discusses regulatory issues related to disclosure violations and the impact on credit ratings of certain bonds. The document does not contain financial statements or detailed financial data, nor is it a full report. It is a regulatory announcement about a compliance matter and credit rating implications. The document length is short (1449 characters), and it is clearly an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance-related disclosures that do not fit other categories.
2019-01-09 Chinese
关于公司收到中国证监会山东监管局警示函的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from 瑞康医药集团股份有限公司 regarding receipt of a warning letter from the China Securities Regulatory Commission Shandong Bureau. It details regulatory findings about the company's failure to disclose related party transactions in prior reports, the regulatory basis for the warning, and the company's corrective actions. The document is short (1181 characters) and does not contain financial statements or detailed financial data. It is a regulatory announcement about a compliance issue and corrective plan, not a full audit report or annual report. It fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure that does not fit other categories.
2019-01-04 Chinese
第三届董事会第十八次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 18th meeting of the 3rd Board of Directors of Ruikang Pharmaceutical Group Co., Ltd. It includes details about strategic cooperation agreements, guarantees for subsidiaries, amendments to the company's articles of association, and the scheduling of an upcoming extraordinary general meeting. The document contains voting results and procedural details about board decisions but does not include financial statements or detailed financial analysis. It is a formal disclosure of board meeting decisions, which fits the category of Board/Management Information (MANG). The document length is 2325 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2019-01-02 Chinese
关于公司与深圳市招商慧合股权投资基金管理有限公司签署战略合作协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a strategic cooperation agreement between the company 瑞康医药集团股份有限公司 and 深圳市招商慧合股权投资基金管理有限公司. It details the nature of the agreement, the parties involved, the cooperation principles, investment directions, and risk warnings. There are no financial statements, no quarterly or annual financial results, no audit opinions, no voting results, no executive changes, and no earnings highlights. The document is a formal announcement of a strategic partnership agreement, which is a capital/financing update type of disclosure as it relates to investment cooperation and potential capital activities. The document length is 2682 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-01-02 Chinese
独立董事关于公司为控股子公司提供担保事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors of 瑞康医药集团股份有限公司 regarding the company's provision of guarantees for its controlling subsidiaries. It references compliance with regulatory notices from the China Securities Regulatory Commission about external guarantees and confirms the procedural legality and appropriateness of the guarantee. The document is short (834 characters) and does not contain financial statements or detailed financial data. It is a formal opinion related to a specific corporate governance matter rather than a full report or announcement of voting results. It does not fit into categories like Annual Report, Audit Report, or Earnings Release. It is not a voting result announcement or a proxy solicitation. The document is best classified as a Regulatory Filing (RNS) because it is a compliance-related statement by independent directors on a corporate governance issue that does not fit other categories.
2019-01-02 Chinese
关于召开2019年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2019 first extraordinary general meeting (临时股东大会) of 瑞康医药集团股份有限公司. It includes information about the meeting time, location, voting procedures (both onsite and online), eligibility to attend, agenda items to be voted on, and proxy voting instructions. There is no financial data, earnings information, or audit content. The document is not a report itself but a formal announcement and invitation to shareholders to attend and vote at the meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document length is about 4531 characters, which is consistent with a detailed meeting notice rather than a full report. Therefore, the correct classification is PSI.
2019-01-02 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.